

Wolfram Doehner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1244017/publications.pdf>

Version: 2024-02-01

286
papers

22,300
citations

10389

72
h-index

10158

140
g-index

296
all docs

296
docs citations

296
times ranked

23294
citing authors

#	ARTICLE	IF	CITATIONS
1	Frailty Consensus: A Call to Action. Journal of the American Medical Directors Association, 2013, 14, 392-397.	2.5	2,839
2	Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure. Circulation, 2000, 102, 3060-3067.	1.6	723
3	Nutritional Recommendations for the Management of Sarcopenia. Journal of the American Medical Directors Association, 2010, 11, 391-396.	2.5	548
4	Uric Acid and Survival in Chronic Heart Failure. Circulation, 2003, 107, 1991-1997.	1.6	532
5	Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure. Circulation, 2002, 105, 2619-2624.	1.6	518
6	Altered Intestinal Function in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1561-1569.	2.8	499
7	Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). European Heart Journal, 2013, 34, 512-519.	2.2	472
8	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	7.1	434
9	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet, The, 2020, 396, 1895-1904.	13.7	425
10	Sarcopenia: A Time for Action. An SCWD Position Paper. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 956-961.	7.3	410
11	Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1054-1060.	2.8	397
12	Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2021, 28, 460-495.	1.8	388
13	The relationship between cholesterol and survival in patients with chronic heart failure. Journal of the American College of Cardiology, 2003, 42, 1933-1940.	2.8	361
14	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. American Journal of Hematology, 2017, 92, 1068-1078.	4.1	290
15	Body mass and survival in patients with chronic heart failure without cachexia: The importance of obesity. Journal of Cardiac Failure, 2003, 9, 29-35.	1.7	281
16	Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. European Journal of Heart Failure, 2016, 18, 786-795.	7.1	270
17	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. JACC: Heart Failure, 2015, 3, 136-145.	4.1	265
18	Peripheral Chemoreceptor Hypersensitivity. Circulation, 2001, 104, 544-549.	1.6	264

#	ARTICLE	IF	CITATIONS
19	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2017, 19, 821-836.	7.1	252
20	Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1019-1026.	2.8	249
21	Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. <i>Cardiovascular Research</i> , 2007, 73, 298-309.	3.8	227
22	Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 899-906.	1.7	227
23	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 326-336.	1.6	222
24	Stroke induced Sarcopenia: Muscle wasting and disability after stroke. <i>International Journal of Cardiology</i> , 2013, 170, 89-94.	1.7	211
25	Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. <i>Journal of the American College of Cardiology</i> , 2001, 38, 443-452.	2.8	200
26	Metabolic Impairment in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1388-1400.	2.8	196
27	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294.	1.6	195
28	Overweight and obesity are associated with improved survival, functional outcome, and stroke recurrence after acute stroke or transient ischaemic attack: observations from the TEMPiS trial. <i>European Heart Journal</i> , 2013, 34, 268-277.	2.2	190
29	Searching for Atrial Fibrillation Poststroke. <i>Circulation</i> , 2019, 140, 1834-1850.	1.6	184
30	Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2012, 157, 80-85.	1.7	180
31	Intestinal Blood Flow in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1092-1102.	2.8	178
32	Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: An analysis of the PROactive study population. <i>International Journal of Cardiology</i> , 2012, 162, 20-26.	1.7	177
33	Uric Acid-Lowering Treatment With Benzbromarone in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 73-81.	3.9	167
34	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. <i>European Heart Journal</i> , 2014, 35, 932-941.	2.2	167
35	Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life. <i>International Journal of Cardiology</i> , 2016, 222, 41-46.	1.7	166
36	Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 1684-1691.	2.2	165

#	ARTICLE	IF	CITATIONS
37	Anemia and Inflammation in COPD. <i>Chest</i> , 2005, 127, 825-829.	0.8	161
38	Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. <i>European Journal of Heart Failure</i> , 2011, 13, 670-680.	7.1	157
39	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	7.1	155
40	Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1299-1305.	7.1	144
41	Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1973-1980.	2.8	139
42	Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). <i>European Journal of Heart Failure</i> , 2018, 20, 1580-1587.	7.1	139
43	Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis. <i>Atherosclerosis</i> , 2015, 242, 496-503.	0.8	136
44	Stroke-heart syndrome: clinical presentation and underlying mechanisms. <i>Lancet Neurology</i> , The, 2018, 17, 1109-1120.	10.2	135
45	Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 81-86.	7.3	134
46	Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. <i>European Journal of Heart Failure</i> , 2018, 20, 199-215.	7.1	128
47	The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 399-406.	1.6	125
48	Stroke-Related Sarcopenia: Specific Characteristics. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 272-276.	2.5	124
49	Body Weight After Stroke. <i>Stroke</i> , 2011, 42, 3646-3650.	2.0	123
50	Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 484-491.	7.1	117
51	Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). <i>Journal of Translational Medicine</i> , 2022, 20, 138.	4.4	116
52	The obesity paradox in chronic disease: facts and numbers. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012, 3, 1-4.	7.3	106
53	Muscle wasting in heart failure: An overview. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 2257-2265.	2.8	106
54	The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure. <i>International Journal of Cardiology</i> , 2016, 205, 6-12.	1.7	104

#	ARTICLE	IF	CITATIONS
55	Cardiac cachexia: hic et nunc. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 246-260.	7.3	103
56	The obesity paradox: weighing the benefit. <i>European Heart Journal</i> , 2010, 31, 146-148.	2.2	101
57	Cardiovascular Function and Predictors of Exercise Capacity in Patients With Colorectal Cancer. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1310-1319.	2.8	93
58	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. <i>European Journal of Heart Failure</i> , 2018, 20, 1664-1672.	7.1	92
59	Uric acid in cachectic and noncachectic patients with chronic heart failure: Relationship to leg vascular resistance. <i>American Heart Journal</i> , 2001, 141, 792-799.	2.7	90
60	Inflammatory Biomarkers in Heart Failure Revisited: Much More than Innocent Bystanders. <i>Heart Failure Clinics</i> , 2009, 5, 549-560.	2.1	87
61	Sarcopenia in stroke—facts and numbers on muscle loss accounting for disability after stroke. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 5-8.	7.3	87
62	Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. <i>European Heart Journal</i> , 2007, 28, 821-828.	2.2	86
63	Dysfunction of respiratory muscles in critically ill patients on the intensive care unit. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 403-412.	7.3	86
64	Anorexia in chronic obstructive pulmonary disease—Association to cachexia and hormonal derangement. <i>International Journal of Cardiology</i> , 2007, 119, 83-89.	1.7	84
65	Immunoabsorption to remove β_2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. <i>PLoS ONE</i> , 2018, 13, e0193672.	2.5	83
66	Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival. <i>International Journal of Cardiology</i> , 2004, 96, 397-401.	1.7	81
67	Cardiac muscle wasting in individuals with cancer cachexia. <i>ESC Heart Failure</i> , 2017, 4, 458-467.	3.1	80
68	Catabolic Signaling and Muscle Wasting After Acute Ischemic Stroke in Mice. <i>Stroke</i> , 2014, 45, 3675-3683.	2.0	79
69	HIGH TUMOUR NECROSIS FACTOR- β LEVELS ARE ASSOCIATED WITH EXERCISE INTOLERANCE AND NEUROHORMONAL ACTIVATION IN CHRONIC HEART FAILURE PATIENTS. <i>Cytokine</i> , 2001, 15, 80-86.	3.2	77
70	Effect of interleukin-10 on the production of tumor necrosis factor- α by peripheral blood mononuclear cells from patients with chronic heart failure. <i>American Journal of Cardiology</i> , 2002, 90, 384-389.	1.6	77
71	Muscle wasting as an independent predictor of survival in patients with chronic heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1242-1249.	7.3	76
72	Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2010, 1, 187-194.	7.3	75

#	ARTICLE	IF	CITATIONS
73	Xanthine Oxidase and Uric Acid in Cardiovascular Disease: Clinical Impact and Therapeutic Options. <i>Seminars in Nephrology</i> , 2011, 31, 433-440.	1.6	75
74	Ursodeoxycholic Acid in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 585-592.	2.8	74
75	Frailty and heart disease. <i>International Journal of Cardiology</i> , 2013, 168, 1745-1747.	1.7	74
76	Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha. <i>International Journal of Cardiology</i> , 2002, 83, 73-81.	1.7	72
77	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.	2.2	71
78	Absolute and functional iron deficiency in professional athletes during training and recovery. <i>International Journal of Cardiology</i> , 2012, 156, 186-191.	1.7	68
79	Sarcopenia, cachexia, and muscle performance in heart failure: Review update 2016. <i>International Journal of Cardiology</i> , 2017, 238, 5-11.	1.7	68
80	Improving exercise capacity and quality of life using noninvasive heart failure treatments: evidence from clinical trials. <i>European Journal of Heart Failure</i> , 2021, 23, 92-113.	7.1	67
81	Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life. <i>Clinical Research in Cardiology</i> , 2019, 108, 203-211.	3.3	62
82	Iron Status and Survival in Diabetic Patients With Coronary Artery Disease. <i>Diabetes Care</i> , 2013, 36, 4147-4156.	8.6	61
83	Detection of muscle wasting in patients with chronic heart failure using C-terminal agrin fragment: results from the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). <i>European Journal of Heart Failure</i> , 2015, 17, 1283-1293.	7.1	61
84	Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. <i>European Heart Journal</i> , 2020, 41, 2668-2677.	2.2	60
85	The anabolic catabolic transforming agent (ACTA) espidolol increases muscle mass and decreases fat mass in old rats. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014, 5, 149-158.	7.3	58
86	The relationship between tumor necrosis factor- α , brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2010, 141, 39-43.	1.7	57
87	Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014, 5, 27-34.	7.3	57
88	Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 50-56.	2.6	56
89	Uric acid and xanthine oxidase in heart failure – Emerging data and therapeutic implications. <i>International Journal of Cardiology</i> , 2016, 213, 15-19.	1.7	56
90	Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). <i>ESC Heart Failure</i> , 2017, 4, 448-457.	3.1	56

#	ARTICLE	IF	CITATIONS
91	Chronic Kidney Disease and Cerebrovascular Disease. <i>Stroke</i> , 2021, 52, e328-e346.	2.0	56
92	Expert opinion paper on atrial fibrillation detection after ischemic stroke. <i>Clinical Research in Cardiology</i> , 2018, 107, 871-880.	3.3	55
93	Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. <i>International Journal of Cancer</i> , 2012, 131, 2187-2196.	5.1	51
94	Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 555-566.	7.3	51
95	Sarcopenia and Endothelial Function in Patients With Chronic Heart Failure: Results From the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). <i>Journal of the American Medical Directors Association</i> , 2017, 18, 240-245.	2.5	51
96	Chronic heart failure in the very elderly: Clinical status, survival, and prognostic factors in 188 patients more than 70 years old. <i>American Heart Journal</i> , 2001, 142, 174-180.	2.7	50
97	IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 105-109.	7.3	50
98	Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. <i>European Journal of Pharmacology</i> , 2007, 569, 204-211.	3.5	48
99	Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2012, 162, 27-32.	1.7	48
100	Nutrition in heart failure: an update. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2009, 12, 384-391.	2.5	47
101	Anaemia is an independent predictor of death in patients hospitalized for acute heart failure. <i>Clinical Research in Cardiology</i> , 2010, 99, 107-113.	3.3	47
102	Liver dysfunction and its nutritional implications in heart failure. <i>Nutrition</i> , 2013, 29, 370-378.	2.4	47
103	TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2013, 168, 1447-1452.	1.7	47
104	Protective overweight in cardiovascular disease: moving from "paradox" to "paradigm". <i>European Heart Journal</i> , 2015, 36, 2729-2732.	2.2	47
105	Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 60-67.	7.3	47
106	Mechanism and novel therapeutic approaches to wasting in chronic disease. <i>Maturitas</i> , 2013, 75, 199-206.	2.4	46
107	Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia. <i>International Journal of Cardiology</i> , 2013, 168, 3412-3418.	1.7	46
108	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 171-180.	3.0	46

#	ARTICLE	IF	CITATIONS
109	Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. ESC Heart Failure, 2020, 7, 1064-1071.	3.1	46
110	Cardiac cachexia in early literature: a review of research prior to Medline. International Journal of Cardiology, 2002, 85, 7-14.	1.7	44
111	Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissue. Journal of Cardiac Failure, 2004, 10, 421-426.	1.7	44
112	The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wiener Klinische Wochenschrift, 2009, 121, 309-313.	1.9	44
113	Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. International Journal of Cardiology, 2010, 138, 19-24.	1.7	44
114	Increased catabolic activity in adipose tissue of patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 1131-1137.	7.1	43
115	Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure. Wiener Klinische Wochenschrift, 2016, 128, 497-504.	1.9	43
116	Iron deficiency in chronic heart failure: case-based practical guidance. ESC Heart Failure, 2018, 5, 764-771.	3.1	43
117	Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. European Heart Journal, 2022, 43, 2442-2460.	2.2	43
118	Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins. European Journal of Heart Failure, 2005, 7, 479-484.	7.1	42
119	Elevated Plasma Levels of Neuropeptide Proenkephalin A Predict Mortality and Functional Outcome in Ischemic Stroke. Journal of the American College of Cardiology, 2012, 60, 346-354.	2.8	42
120	Endothelial Dysfunction of the Peripheral Vascular Bed in the Acute Phase after Ischemic Stroke. Cerebrovascular Diseases, 2012, 33, 37-46.	1.7	41
121	Cardiac cachexia is associated with right ventricular failure and liver dysfunction. International Journal of Cardiology, 2013, 169, 219-224.	1.7	40
122	The Influence of Recovery and Training Phases on Body Composition, Peripheral Vascular Function and Immune System of Professional Soccer Players. PLoS ONE, 2009, 4, e4910.	2.5	39
123	Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. European Heart Journal, 2022, 43, 3435-3446.	2.2	39
124	Uric acid in chronic heart failure. Seminars in Nephrology, 2005, 25, 61-66.	1.6	38
125	Bone marrow iron depletion is common in patients with coronary artery disease. International Journal of Cardiology, 2015, 182, 517-522.	1.7	38
126	The cardiac component of cardiac cachexia. American Heart Journal, 2002, 144, 45-50.	2.7	37

#	ARTICLE	IF	CITATIONS
127	The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy. <i>International Journal of Cardiology</i> , 2013, 168, 3527-3531.	1.7	37
128	Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation. <i>Journal of Molecular Medicine</i> , 2011, 89, 151-160.	3.9	36
129	Insulin resistance in heart failure: differences between patients with reduced and preserved left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 1015-1021.	7.1	36
130	Body weight changes and incidence of cachexia after stroke. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 611-620.	7.3	36
131	Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. <i>International Journal of Cardiology</i> , 2010, 144, 206-211.	1.7	35
132	Flawed methods and inappropriate conclusions for health policy on overweight and obesity: the Global BMI Mortality Collaboration meta-analysis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 9-13.	7.3	35
133	Influence of Diabetes Mellitus and Hyperglycemia on Prognosis in Patients ≥70 Years Old With Heart Failure and Effects of Nebivolol (Data from the Study of Effects of Nebivolol Intervention on) <i>Tj ETQq1 1 0.784314 156 / Overlock 10 34</i> <i>Cardiology</i> , 2010, 106, 78-86.e1.	1.7	34
134	Leukocyte Redistribution: Effects of Beta Blockers in Patients with Chronic Heart Failure. <i>PLoS ONE</i> , 2009, 4, e6411.	2.5	34
135	Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1. <i>PLoS ONE</i> , 2011, 6, e14506.	2.5	34
136	Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study. <i>International Journal of Cardiology</i> , 2004, 97, 15-20.	1.7	33
137	Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. <i>ESC Heart Failure</i> , 2017, 4, 274-281.	3.1	33
138	Exercise capacity and body composition in living-donor renal transplant recipients over time. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3854-3860.	0.7	32
139	Cachexia as a common characteristic in multiple chronic disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1189-1191.	7.3	32
140	Hand grip strength and fatigability: correlation with clinical parameters and diagnostic suitability in ME/CFS. <i>Journal of Translational Medicine</i> , 2021, 19, 159.	4.4	31
141	Cachexia in heart disease: highlights from the ESC 2010. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 63-69.	7.3	29
142	Heart-brain Interactions in Heart Failure. <i>Cardiac Failure Review</i> , 2018, 4, 87.	3.0	29
143	Elevated Levels of Asymmetric Dimethylarginine in Chronic Heart Failure: A Pathophysiologic Link Between Oxygen Radical Load and Impaired Vasodilator Capacity and the Therapeutic Effect of Allopurinol. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 506-512.	4.7	28
144	Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia. <i>International Journal of Cardiology</i> , 2013, 170, 160-166.	1.7	28

#	ARTICLE	IF	CITATIONS
145	Skeletal muscle weakness is related to insulin resistance in patients with chronic heart failure. ESC Heart Failure, 2015, 2, 85-89.	3.1	28
146	Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure – Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Circulation Journal, 2017, 81, 52-61.	1.6	28
147	Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS). Journal of Cachexia, Sarcopenia and Muscle, 2013, 4, 199-207.	7.3	27
148	Febuxostat improves outcome in a rat model of cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 174-180.	7.3	27
149	The importance of return to work: How to achieve optimal reintegration in ACS patients. European Journal of Preventive Cardiology, 2019, 26, 1358-1369.	1.8	27
150	Hormonal consequences and prognosis of chronic heart failure. Current Opinion in Endocrinology, Diabetes and Obesity, 2011, 18, 224-230.	2.3	26
151	Ursodeoxycholic acid treatment in a rat model of cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 31-36.	7.3	26
152	Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the <sc>MOLITOR</sc> study. ESC Heart Failure, 2018, 5, 288-296.	3.1	26
153	Intensified secondary prevention intending a reduction of recurrent events in TIA and minor stroke patients (INSPIRE-TMS): a protocol for a randomised controlled trial. BMC Neurology, 2013, 13, 11.	1.8	24
154	Cellular endotoxin desensitization in patients with severe chronic heart failure. European Journal of Heart Failure, 2005, 7, 865-868.	7.1	23
155	Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review. Wiener Klinische Wochenschrift, 2009, 121, 293-296.	1.9	23
156	Neurological and endocrinological disorders: orphans in chronic obstructive pulmonary disease. Respiratory Medicine, 2011, 105, S12-S19.	2.9	23
157	Micronutrient Depletion in Heart Failure: Common, Clinically Relevant and Treatable. International Journal of Molecular Sciences, 2019, 20, 5627.	4.1	23
158	Uric acid as a prognostic marker in acute heart failure - new expectations from an old molecule. European Journal of Heart Failure, 2007, 9, 437-439.	7.1	22
159	Critical appraisal of the obesity paradox in cardiovascular disease: How to manage patients with overweight in heart failure?. Heart Failure Reviews, 2014, 19, 637-644.	3.9	22
160	Animal models of cachexia and sarcopenia in chronic illness: Cardiac function, body composition changes and therapeutic results. International Journal of Cardiology, 2017, 238, 12-18.	1.7	22
161	Adiponectin Resistance in Heart Failure and the Emerging Pattern of Metabolic Failure in Chronic Heart Failure. Circulation: Heart Failure, 2010, 3, 181-182.	3.9	21
162	Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia. Nutrition, 2014, 30, 1069-1075.	2.4	21

#	ARTICLE	IF	CITATIONS
163	Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2014, 171, 398-403.	1.7	21
164	Ischemic stroke and heart failure: facts and numbers. <i>ESC Heart Failure</i> , 2015, 2, 1-4.	3.1	21
165	The role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke. <i>European Heart Journal</i> , 2018, 39, 1567-1573.	2.2	21
166	Revisiting the obesity paradox in heart failure: new insights?. <i>European Journal of Heart Failure</i> , 2011, 13, 130-132.	7.1	20
167	Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012, 3, 45-50.	7.3	20
168	High-sensitivity cardiac troponin T and severity of cerebral white matter lesions in patients with acute ischemic stroke. <i>Journal of Neurology</i> , 2019, 266, 37-45.	3.6	20
169	Delphi consensus recommendations on how to provide cardiovascular rehabilitation in the COVID-19 era. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 541-557.	1.8	20
170	Obesity and the Heart. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2274-2276.	2.8	19
171	Insulin Resistance in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 239.	2.8	19
172	Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2011, 147, 47-51.	1.7	18
173	The small intestine: A critical linkage in pathophysiology of cardiac cachexia. <i>International Journal of Cardiology</i> , 2011, 146, 277-278.	1.7	18
174	Resting Energy Expenditure and the Effects of Muscle Wasting in Patients With Chronic Heart Failure: Results From the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). <i>Journal of the American Medical Directors Association</i> , 2013, 14, 837-841.	2.5	18
175	Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain. <i>Cmaj</i> , 2013, 185, E295-E303.	2.0	18
176	Cardiac cachexia: hic et nunc. <i>International Journal of Cardiology</i> , 2015, 201, e1-e12.	1.7	18
177	A tissue-specific screen of ceramide expression in aged mice identifies ceramide synthase 1 and ceramide synthase 5 as potential regulators of fiber size and strength in skeletal muscle. <i>Aging Cell</i> , 2020, 19, e13049.	6.7	18
178	Interdisciplinary management of acute ischaemic stroke: Current evidence training requirements for endovascular stroke treatment: Position Paper from the ESC Council on Stroke and the European Association for Percutaneous Cardiovascular Interventions with the support of the European Board of Neurointervention. <i>European Heart Journal</i> , 2021, 42, 298-307.	2.2	18
179	Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2020, 7, 3392-3400.	3.1	18
180	The relationship between age and production of tumour necrosis factor- α in healthy volunteers and patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2003, 90, 197-204.	1.7	17

#	ARTICLE	IF	CITATIONS
181	Heart failure therapy: testosterone replacement and its implicationsThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2006, 27, 10-12.	2.2	17
182	Uric acid in CHF: Marker or player in a metabolic disease?. International Journal of Cardiology, 2007, 115, 156-158.	1.7	17
183	Risk stratification in patients with chronic heart failure based on metabolic-immunological, functional and haemodynamic parameters. International Journal of Cardiology, 2012, 156, 62-68.	1.7	17
184	Obesity and long-term outcomes after incident stroke: a prospective population-based cohort study. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 2111-2121.	7.3	17
185	Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model. International Journal of Cardiology, 2013, 168, 2369-2374.	1.7	16
186	Dementia and the heart failure patient. European Heart Journal Supplements, 2019, 21, L28-L31.	0.1	16
187	Metabolic disturbances in chronic heart failure: A case for the "macho" approach with testosterone?. European Journal of Heart Failure, 2007, 9, 2-3.	7.1	15
188	Uric acid in chronic heart failure"current pathophysiological concepts*. European Journal of Heart Failure, 2008, 10, 1269-1270.	7.1	15
189	Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 325-334.	7.3	15
190	Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. European Journal of Preventive Cardiology, 2020, 27, 682-692.	1.8	15
191	MT-102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 594-605.	7.3	15
192	Lipopolysaccharide responsiveness is an independent predictor of death in patients with chronic heart failure. Journal of Molecular and Cellular Cardiology, 2015, 87, 48-53.	1.9	14
193	Could gonadal and adrenal androgen deficiencies contribute to the depressive symptoms in men with systolic heart failure?. Aging Male, 2016, 19, 221-230.	1.9	14
194	Sleep-Disordered Breathing in Acute Ischemic Stroke: A Mechanistic Link to Peripheral Endothelial Dysfunction. Journal of the American Heart Association, 2017, 6, .	3.7	14
195	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension. Journal of Hypertension, 2016, 34, 1678-1688.	0.5	13
196	Early rehabilitation after stroke: relationship between the heart rate variability and functional outcome. ESC Heart Failure, 2020, 7, 2983-2991.	3.1	13
197	The effect of iron deficiency on cardiac resynchronization therapy: results from the RIDE-CRT Study. ESC Heart Failure, 2020, 7, 1072-1084.	3.1	13
198	ESC Working Group on e-Cardiology Position Paper: accuracy and reliability of electrocardiogram monitoring in the detection of atrial fibrillation in cryptogenic stroke patients. European Heart Journal Digital Health, 2022, 3, 341-358.	1.7	13

#	ARTICLE	IF	CITATIONS
199	Defects in insulin action in chronic heart failure. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 203-212.	4.4	12
200	Optimizing Insulin Sensitivity Assessment Using the Minimal Model in Chronic Heart Failure. <i>Hormone and Metabolic Research</i> , 2005, 37, 106-110.	1.5	12
201	Furosemide induces mortality in a rat model of chronic heart failure. <i>International Journal of Cardiology</i> , 2012, 160, 20-25.	1.7	12
202	Single baseline serum creatinine measurements predict mortality in critically ill patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2015, 2, 122-128.	3.1	12
203	Expert opinion paper on cardiac imaging after ischemic stroke. <i>Clinical Research in Cardiology</i> , 2021, 110, 938-958.	3.3	12
204	Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease. <i>Clinical Science</i> , 2012, 123, 601-610.	4.3	11
205	Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: A randomized double-blinded placebo-controlled study. <i>International Journal of Cardiology</i> , 2012, 161, 137-142.	1.7	11
206	Influence of essential amino acids on muscle mass and muscle strength in patients with cerebral stroke during early rehabilitation: protocol and rationale of a randomized clinical trial (AMINO-Stroke Study). <i>BMC Neurology</i> , 2016, 16, 10.	1.8	11
207	Ischemic Stroke and Heart Failure: Facts and Numbers. An Update. <i>Journal of Clinical Medicine</i> , 2021, 10, 1146.	2.4	11
208	Association of Deranged Adrenal Steroid Metabolism With Anemia in Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2005, 96, 101-103.	1.6	10
209	Diagnostic biomarkers in cardiovascular disease: the proteomics approach. <i>European Heart Journal</i> , 2012, 33, 2249-2251.	2.2	10
210	Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study. <i>Archives of Medical Science</i> , 2013, 2, 261-267.	0.9	10
211	Impact of chronic inflammatory airway disease on stroke severity and long-term survival after ischemic stroke - a retrospective analysis. <i>BMC Neurology</i> , 2015, 15, 164.	1.8	10
212	Iron deficiency is related to low functional outcome in patients at early rehabilitation after acute stroke. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1036-1044.	7.3	10
213	Assessment of serum cotinine in patients with chronic heart failure: self-reported versus objective smoking behaviour. <i>Clinical Research in Cardiology</i> , 2013, 102, 95-101.	3.3	9
214	The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2016, 219, 84-91.	1.7	9
215	Influence of core body temperature on Tryptophan metabolism, kynurenines, and estimated IDO activity in critically ill patients receiving target temperature management following cardiac arrest. <i>Resuscitation</i> , 2016, 107, 107-114.	3.0	9
216	The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. <i>Europace</i> , 2021, 23, 314-322.	1.7	9

#	ARTICLE	IF	CITATIONS
217	Beta blockers and glucose metabolism in chronic heart failure: Friend or foe?. <i>Clinical Research in Cardiology</i> , 2008, 97, 21-23.	3.3	8
218	Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly?. <i>Aging Male</i> , 2013, 16, 123-131.	1.9	8
219	Effect of Exogenous Intravenous Administrations of GLP-1 and/or GIP on Circulating Pro-Atrial Natriuretic Peptide in Subjects With Different Stages of Glucose Tolerance. <i>Diabetes Care</i> , 2015, 38, e7-e8.	8.6	8
220	Searching for a relevant definition of sarcopenia: results from the cross-sectional EPIDOS study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 100-101.	7.3	8
221	Do we need a reference standard for the muscle mass measurements?. <i>ESC Heart Failure</i> , 2018, 5, 741-744.	3.1	8
222	Severe Weight Loss and Its Association with Fatigue in Old Patients at Discharge from a Geriatric Hospital. <i>Nutrients</i> , 2019, 11, 2415.	4.1	8
223	The importance of rehabilitation in the secondary prevention of cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 273-276.	1.8	8
224	The significance of Leptin in human â€” do we know it yet?. <i>International Journal of Cardiology</i> , 2000, 76, 122-124.	1.7	7
225	Sinus rhythm versus atrial fibrillation in elderly patients with chronic heart failure â€” Insight from the Cardiac Insufficiency Bisoprolol Study in Elderly. <i>International Journal of Cardiology</i> , 2012, 161, 160-165.	1.7	7
226	Longer-term impact of hemiparetic stroke on skeletal muscle metabolismâ€”A pilot study. <i>International Journal of Cardiology</i> , 2017, 230, 241-247.	1.7	7
227	Transgenerational transmission of an anticholinergic endophenotype with memory dysfunction. <i>Neurobiology of Aging</i> , 2017, 51, 19-30.	3.1	7
228	Differentiating between body fat and lean massâ€”how should we measure obesity?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, E1-E1.	2.8	7
229	Serum phosphorus level is related to degree of clinical response to up-titration of heart failure pharmacotherapy. <i>International Journal of Cardiology</i> , 2014, 177, 248-254.	1.7	6
230	The Obesity Paradigm and Lifetime Risk of Cardiovascular Disease. <i>JAMA Cardiology</i> , 2018, 3, 895.	6.1	6
231	Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies. <i>ESC Heart Failure</i> , 2020, 7, 3086-3094.	3.1	6
232	Personalized anti-thrombotic management of patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1â€”a statement of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke. <i>European Heart Journal</i> , 2021, 42, 541-543.	2.2	6
233	Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm: An updated systematic review and meta-analysis of randomized clinical trials. <i>International Journal of Stroke</i> , 2023, 18, 392-399.	5.9	6
234	Weight Change with Beta-blocker Use: A Side Effect Put into Perspective. <i>American Journal of Medicine</i> , 2008, 121, e15.	1.5	5

#	ARTICLE	IF	CITATIONS
235	Overview of emerging pharmacotherapy in chronic heart failure. Expert Opinion on Pharmacotherapy, 2009, 10, 2055-2074.	1.8	5
236	Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival. ESC Heart Failure, 2014, 1, 41-51.	3.1	5
237	A direct link between haemodynamic failure and inflammatory activation in heart failure: the simplified approach to heart failure and to creation of life. European Heart Journal, 2014, 35, 413-415.	2.2	5
238	The role of cardiologists on the stroke unit. European Heart Journal Supplements, 2020, 22, M3-M12.	0.1	5
239	RNAs in Brain and Heart Diseases. International Journal of Molecular Sciences, 2020, 21, 3717.	4.1	5
240	Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study. Journal of Clinical Medicine, 2021, 10, 2420.	2.4	5
241	Iron Deficiency and Reduced Muscle Strength in Patients with Acute and Chronic Ischemic Stroke. Journal of Clinical Medicine, 2022, 11, 595.	2.4	5
242	Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?. Journal of Clinical Medicine, 2022, 11, 2976.	2.4	5
243	Anaemia predicts health related quality of life in heart failure patients. International Journal of Cardiology, 2013, 162, 67-68.	1.7	4
244	Vasodilation and Exercise Capacity in Patients with End-Stage Renal Disease: A Prospective Proof-of-Concept Study. CardioRenal Medicine, 2017, 7, 50-59.	1.9	4
245	Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1. European Heart Journal, 2019, 40, 3010-3012.	2.2	4
246	The evolving obesity paradigm story: from heart failure to atrial fibrillation. European Heart Journal, 2019, 40, 1550-1552.	2.2	4
247	Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. Europace, 2021, 23, 806-814.	1.7	4
248	Andropausal syndrome in men with systolic heart failure. Polish Archives of Internal Medicine, 2013, 123, 156-169.	0.4	4
249	Questions in Cardiac Resynchronization Therapy: Metabolic Implications. Journal of the American College of Cardiology, 2006, 48, 591-592.	2.8	3
250	Overweight, Obesity, and All-Cause Mortality. JAMA - Journal of the American Medical Association, 2013, 309, 1679.	7.4	3
251	Smoking and Other Risk Factors in Type 2 Diabetes. New England Journal of Medicine, 2018, 379, 2572-2575.	27.0	3
252	Intravenous iron supplementation is state of the art therapy in patients with heart failure and iron deficiency. European Journal of Heart Failure, 2019, 21, 1165-1165.	7.1	3

#	ARTICLE	IF	CITATIONS
253	Acute effects of oral triglyceride load on dynamic changes in peripheral endothelial function in heart failure patients with reduced ejection fraction and healthy controls. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1961-1966.	2.6	3
254	Abnormal serum calcium levels are associated with clinical response to maximization of heart failure therapy. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 54-64.	0.4	3
255	Anorexia in chronic obstructive pulmonary disease – Association to cachexia and hormonal derangement. <i>International Journal of Cardiology</i> , 2009, 132, 434.	1.7	2
256	How to Determine a Metabolically Healthy Body Composition in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1182-1183.	2.8	2
257	The Impact of Body Weight on Mortality After Stroke. <i>JAMA Neurology</i> , 2015, 72, 126.	9.0	2
258	Comorbidities of chronic heart failure – a systemic syndrome requiring cross-specialty efforts. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 79-82.	1.5	2
259	Heart-brain interactions in patients with heart failure, including takotsubo syndrome: a need to monitor autonomic sympathetic activity: reply. <i>European Journal of Heart Failure</i> , 2018, 20, 1164-1165.	7.1	2
260	Central command in heart failure: was there effect of hemispheric lateralization in insular cortex activation? Reply. <i>European Journal of Heart Failure</i> , 2018, 20, 1370-1371.	7.1	2
261	Comment on “Weight loss in heart failure is associated with increased mortality only in non-obese patients without diabetes” by Niedziela et al .. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1867-1868.	7.3	2
262	The obesity paradigm in cardiovascular disease: the need for differentiated weight management. <i>European Heart Journal</i> , 2020, 41, 3965-3965.	2.2	2
263	Comment on: “Handgrip weakness, low fat-free mass, and overall survival in nonsmall cell lung cancer treated with curative-intent radiotherapy” by Burtin et al.. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1863-1864.	7.3	2
264	Comment on: “Experimental ischaemic stroke induces transient cardiac atrophy” by Veltkamp et al .. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1865-1866.	7.3	2
265	Cardiac Cachexia in Chronic Heart Failure: The Metabolic Facet of CHF. , 2010, , 165-185.		2
266	Comment on Hinnouho et al. Metabolically Healthy Obesity and Risk of Mortality: Does the Definition of Metabolic Health Matter? <i>Diabetes Care</i> 2013;36:2294-2300. <i>Diabetes Care</i> , 2014, 37, e104-e104.	8.6	1
267	Meeting highlights from the 2013 European Society of Cardiology Heart Failure Association Winter Meeting on Translational Heart Failure Research. <i>European Journal of Heart Failure</i> . 2014. 16. 6-14.	7.1	1
268	Estimating fat mass in heart failure patients. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2016, 1, 78-89.	1.0	1
269	Relevance of Heart Failure in Prevention, Treatment and Prognosis of Ischemic Stroke. <i>Neurology International Open</i> , 2017, 1, E61-E64.	0.4	1
270	Nutrient pattern analysis in critically ill patients using Omics technology (NACHO) – Study protocol for a prospective observational study. <i>Medicine (United States)</i> , 2019, 98, e13937.	1.0	1

#	ARTICLE	IF	CITATIONS
271	Stroke patients need cardiologists. <i>European Heart Journal</i> , 2020, 41, 2514-2516.	2.2	1
272	Mental involvement in heart failure. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 557-559.	0.5	1
273	Stroke as Interdisciplinary Disease: What the Practising Cardiologist Can Do. , 0, 18, .		1
274	Survival and body fat in hemodialysis patients: true association or effects of concomitant therapy?. <i>American Journal of Clinical Nutrition</i> , 2006, 84, 663-664.	4.7	0
275	Response to Letter Regarding Article, "Uric Acid-Lowering Treatment With Benzbromarone in Patients With Heart Failure: A Double-Blind Placebo-Controlled Cross-Over Preliminary Study" <i>Circulation: Heart Failure</i> , 2010, 3, .	3.9	0
276	Losartan: the dose does it. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2117-2119.	1.8	0
277	Alterations in Nutrition and Body Mass in Heart Failure. , 2011, , 330-345.		0
278	Letter by Doehner et al Regarding Article, "Association Between Obesity and Mortality After Acute First-Ever Stroke: The Obesity"Stroke Paradox" <i>Stroke</i> , 2011, 42, e395; author reply e396.	2.0	0
279	Insulin Sensitivity, but Not Hyperglycemia, May Be Superior as a Prognostic Marker and Therapeutic Target for Diabetes in Heart Failure. <i>American Journal of Cardiology</i> , 2012, 110, 1070.	1.6	0
280	When a reference value makes all the difference. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012, 3, 141-141.	7.3	0
281	Response to the Letter to the Editor From Xue and Varadhan Titled "What Is Missing in the Validation of Frailty Instruments?" <i>Journal of the American Medical Directors Association</i> , 2014, 15, 147.	2.5	0
282	Interdisciplinary stroke care in 2020: the need for cardiologists to learn about stroke. <i>European Heart Journal Supplements</i> , 2020, 22, M1-M2.	0.1	0
283	Proenkephalin A as Potential Prognostic Biomarker in Acute Ischemic Stroke. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962094503.	1.7	0
284	Beware of TOSCA's kiss or metabolic and hormonal aspects of heart failure. <i>European Journal of Preventive Cardiology</i> , 2021, , .	1.8	0
285	Mental involvement in heart failure. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 557-559.	0.2	0
286	Xanthine Oxidase Inhibitors and Insulin Sensitizers. , 2005, , 451-472.		0